Naoki Furuya, MD, PhD, on NSCLC: Results From the NEJ026 Study
2018 ASCO Annual MeetingNaoki Furuya, MD, PhD, of the St. Marianna University School of Medicine, discusses phase III study findings on a comparison of bevacizumab plus erlotinib to erlotinib in patients with untreated non–small cell lung cancer with activating EGFR mutations (Abstract 9006).
Related Videos
Kathleen N. Moore, MD, on Ovarian Cancer: Results From the QUADRA Study
Kathleen N. Moore, MD, of the University of Oklahoma Health Sciences Center, discusses phase II study findings on niraparib in patients with relapsed ovarian cancer who have receiv...
Toni K. Choueiri, MD, and Elizabeth R. Plimack, MD, on RCC: Perspectives on KEYNOTE-427 and IMmotion151
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, offer their analysis of two key studies presented ...
Susan Halabi, PhD, on Prostate Cancer: Overall Survival for Black vs White Men
Susan Halabi, PhD, of Duke University Medical Center, discusses an analysis that showed an increase in overall survival in African American men vs Caucasian men, all of whom had me...
Emily S. Ruiz, MD, MPH, on Squamous Cell Carcinoma: Expert Perspective
Emily S. Ruiz, MD, MPH, of Brigham and Women’s Cancer Center, discusses new developments in the treatment of squamous cell skin cancer and what she sees on the therapeutic horizon ...
Andrew D. Seidman, MD, and Aditya Bardia, MD, MPH, on Metastatic Breast Cancer: Findings on an Antibody-Drug Conjugate
Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Aditya Bardia, MD, MPH, of Massachusetts General Hospital, discuss the efficacy of sacituzuma...
